Home > Search Results

Results: 4

Treatments for hidradenitis suppurativa

Hidradenitis suppurativa (HS) is a long‐term, distressing skin condition involving multiple painful boils in skin creases, such as the armpits, groin, and genital region, estimated to affect about 1 in 100 people. It typically begins in early adulthood and has a large impact on quality of life because of pain, scarring, and low self‐esteem. Doctors and the general public have largely ignored the condition, in part because people with HS do not wish to draw attention to their condition, so there is a relative lack of evidence to guide treatment.

Cochrane Database of Systematic Reviews: Plain Language Summaries [Internet] - John Wiley & Sons, Ltd.

Version: 2017

The off-label treatment of severe hidradenitis suppurativa with TNF-alpha inhibitors: a systematic review

To provide an overview of the current evidence regarding off-label treatment of hidradenitis suppurativa (HS) with TNF-α inhibitors, a systematic search was performed in MEDLINE, EMBASE and CENTRAL. Any type of original article concerning HS patients treated with infliximab, etanercept and/or adalimumab was included. No language restriction was applied. After full-text screening 65 studies involving 459 patients met the inclusion criteria and were subjected to data extraction. Four randomized controlled trials (RCTs) were available, and the remainders were case series or reports. Only RTCs were subjected to methodological quality assessment. Based on efficacy data extracted from the case reports, a moderate to good response was seen in 82% of the patients treated with infliximab, 76% of the patients treated with adalimumab, and 68% of the patients treated with etanercept. Due to the moderate level of evidence only a weak recommendation can be provided. If conventional treatment options fail, the use of TNF-α inhibitors can be a useful supplement for the treatment of recurrent severe HS. Infliximab should be preferred based on the most encouraging results regarding efficacy and expenses. Also adalimumab seems promising when administered in higher doses. The use of etanercept should be discouraged.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Systemic therapy with immunosuppressive agents and retinoids in hidradenitis suppurativa: a systematic review

The authors concluded that based on the evidence, infliximab and adalimumab were the most effective immunosuppressive agents for hidradenitis suppurativa. Due to the limited synthesis and evidence presented in the review, the authors' conclusions are unlikely to be reliable.

Database of Abstracts of Reviews of Effects (DARE): Quality-assessed Reviews [Internet] - Centre for Reviews and Dissemination (UK).

Version: 2013

Genetics of Skin Cancer (PDQ®): Health Professional Version

Expert-reviewed information summary about the genetics of skin cancer — basal cell carcinoma, squamous cell carcinoma, and melanoma — including information about specific gene mutations and related cancer syndromes. The summary also contains information about interventions that may influence the risk of developing skin cancer in individuals who may be genetically susceptible to these syndromes.

PDQ Cancer Information Summaries [Internet] - National Cancer Institute (US).

Version: May 11, 2017

Systematic Reviews in PubMed

See all (45)...

Systematic Review Methods in PubMed

See all (1)...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...